Literature DB >> 1399943

Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.

H F Chambers1.   

Abstract

The activity of RP 59500 against methicillin-resistant Staphylococcus aureus was studied in vitro and in a rabbit model of aortic valve endocarditis. Three strains, 67-O, 529, and Du, ranging from relatively resistant to susceptible to RP 59500 in vitro (mean agar dilution MICs of 0.65, 0.21, and 0.12 mg/L respectively) were used to establish endocarditis, which was treated either with RP 59500, 20 mg/kg im four times a day for four days or with vancomycin, 25 mg/kg iv twice a day for four days. RP 59500 was ineffective for the most resistant strain, 67-O. RP 59500 was effective for the intermediately susceptible strain 529, but vancomycin was more effective. RP 59500 was slightly more effective than vancomycin against the most susceptible strain, Du, but the difference was not statistically significant. These results suggest that strains inhibited by RP 59500 at a concentration of greater than or equal to 0.5 mg/L should probably be considered resistant in this model of infection. RP 59500 was effective in vivo against the two susceptible strains, but overall, vancomycin was the more active drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399943     DOI: 10.1093/jac/30.suppl_a.117

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

Authors:  R G Finch
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.

Authors:  Matthew R Moore; Françoise Perdreau-Remington; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

6.  Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.

Authors:  J M Entenza; H Drugeon; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.

Authors:  S L Kang; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.